Publications des membres du service

2008

Ades. S, Koushik. A, Duarte-Franco. E, Mansour. N, Arseneau. J, Provencher. D, et al. for the Biomarkers of Cervical Cancer Risk Study Team. Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. International Journal of Cancer 2008;122(12):2820-6.

2007

Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, Zhang P, Fafard E, Mes-Masson AM, Foulkes WD, Provencher D, Narod SA, Tonin PN: Germline tp53 mutations in brca1 and brca2 mutation-negative french canadian breast cancer families. Breast Cancer Res Treat 2007

Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, Lynch HT, Friedman E, Sun P, Narod SA: And hereditary ovairan cancer clinical study group* including Provencher DM. The risk of endometrial cancer in women with brca1 and brca2 mutations. A prospective study. Gynecol Oncol 2007;104:7-10.

Benoit MH, Hudson TJ, Maire G, Squire JA, Arcand SL, Provencher D, Mes-Masson AM, Tonin PN: Global analysis of chromosome x gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. Int J Oncol 2007;30:5-17.

Birch AH, Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN: Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog 2007

Cody NA, Ouellet V, Manderson EN, Quinn MC, Filali-Mouhim A, Tellis P, Zietarska M, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN: Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene 2007;26:618-632.

Dery M-C, Van Themsche C, Provencher D, Mes-Masson AM, Asselin E: Characterization of en-1078d, a poorly differentiated human endometrial carcinoma cell line : A novel tool to study endometrial invasion in vitro. Reprod Biol  Endocrinol 2007;5:38.

Elit L, Zitzelsberger L, Fung-Kee-Fung M, Brouwers M, Graham ID, Browman G, Hoskins P, Lau S, Ghatage P, Society of Gynecologic Oncologists of Canada* including Provencher D: Use of systemic therapy in women with recurrent ovarian cancer--development of a national clinical practice guideline. . Gynecol Oncol 2007;106:181-192.

Fung-Kee-Fung M, Provencher D, Rosen B, Hoskins P, Rambout L, Oliver T, Gotlieb W, Covens A: Intraperitoneal chemotherapy for patients with advanced ovarian cancer: A review of the evidence and standards for the delivery of care. Gynecologic Oncology 2007;105:747-756.

Horsman D, Wilson BJ, Avard D, Meschino WS, Sing CK, Plante M, Eisen A, Howley HE, Simard J: On behalf of the national hereditary cancer task force including Provencher DM. Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious brca1 or brca2 mutation. JOGC 2007:45-60.

Krasner CN, McMeekin DS, Chan S, Braly PS, GRenshaw FG, Kaye S, Provencher D, Campos S, Gore ME: For the et-743-int-ii study group including Drouin P, Gauthier P, Sauthier P. A phase ii study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007;Nov 13

McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA: And the hereditary ovarian cancer clinical study group* including Provencher DM.  Reproductive risk factors for ovarian cancer in carriers of brca1 or brca2 mutations: A case-control study. Lancet Oncol 2007;8:26-34.

Ouellet V, Le Page C, Madore J, Guyot MC, Barres V, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM: An apoptotic molecular network identified by microarray: On the trail to new insights in epithelial ovarian cancer. Cancer 2007;110:297-308.

Petignat P, du Bois A, Bruchim I, Fink D, Provencher DM: Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer? Critical Reviews in Oncology/Hematology 2007;62:137-147.

Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PM, Chevrette M, Provencher D, Mes-Masson AM: Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in and in vitro model of epithelial ovarian cancer. Neoplasia 2007;9:820-829.

Sauthier P, Petignat P: Diagnostic et prise en charge des neoplasies intraepitheliales vulvaires et des cancers invasifs de la vulve. Gynakol Geburtshilfliche Rundsch 2007;47:88-93.

Schaffer A, Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlee F, Pollak MN, Franco EL: Insulin-like growth factor-i and risk of high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 2007;16:716-722.

Tonin PN, Maugard CM, Perret C, Mes-Masson AM, Provencher DM: A review of histopathological subtypes of ovarian cancer in brca-related french canadian cancer families. Fam Cancer 2007

Williams C, Petignat P, Alobaid A, Provencher D, Gauthier P: Chylous ascites after pelvic lymph node dissection for gynecologic cancer. European Journal of Surgical Oncology 2007;33:399-400.

Wright Jr TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: For the american society for colposcopy and cervical pathology - sponsored consensus conference including provencher dm. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. American Journal of Obstetrics and Gynecology 2007;197:346-355.

Wright Jr TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: For the american society for colposcopy and cervical pathology - sponsored consensus conference including Provencher DM. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. . J Low Genit Tract Dis 2007;Oct 11:201-222.

Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: For the 2006 american society for colposcopy and cervical pathologye - sponsored consensus conference including Provencher DM. 2006 consensus guidelines for the management of women with intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007;197:340-345.

Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: For the 2006 american society for colposcopy and cervical pathologye - sponsored consensus conference including Provencher DM. 2006 consensus guidelines for the management of women with intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 2007;Oct 11:223-239.

Casilli F, Tournier I, Sinilnikova OM, Coulet F, Soubrier F, Houdayer C, Hardouin A, Berthet P, Sobol H, Bourdon V, Muller D, Fricker JP, Provencher DM, Capoulade-Metay C, Chompret A, Nogues C, Mazoyer S, Chappuis P, Maillet P, Philippe C, Lortholary A, Gesta P, Bezieau S, Toulas C, Gladieff L, Maugard CM, Dugast C, Delvincourt C, Nguyen TD, Faivre L, Bonadona V, Frebourg T, Lidereau R, Stoppa-Lyonnet D, Tosi M: The contribution of germline rearrangements to the spectrum of brca2 mutations. J Med Genet 2006;43:e49-.

Elit L, Johnston M, Brouwers M, Fung-Kee-Fung M, Browman G, Graham ID, Society of Gynecologic Oncologists of Canada* including Provencher D: Promoting best gynecologic oncology practice : A role for the society of gynecologic oncologists of canada. Current Oncology 2006;13:1-5.

Faught W, Jeffrey J, Bryson P, Dawson L, Helewa M, Kwon J, Lau S, Lotocki R, Provencher D: Management of squamous cell cancer of the vulva. J Obstet Gynaecol Can 2006;28:640-651.

Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA, for the Hereditary Ovarian Cancer Clinical Study G including Provencher DM: Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a brca1 or brca2 mutation. JAMA 2006;296:185-192.

Ghislain Sangwa-Lugoma, Mahmud S, Nasr SH, Liaras J, Kayembe PK, Tozin RR, Drouin P, Lorincz A, Ferenczy A, Franco EL: Visual inspection as a cervical cancer screening method in a primary health care setting in africa. International Journal of Cancer 2006;119:1389-1395.

Goffin F, Mayrand MH, Gauthier P, Alobaid A, Lussier C, Provencher D, Drouin P, Franco EL, Coutlee F: High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia. J Med Virol 2006;78:814-819.

Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson AM: From gene profiling to diagnostic markers: Il-18 and fgf-2 complement ca125 as serum-based markers in epithelial ovarian cancer. Int J Cancer 2006;118:1750-1758.

Le Page C, Ouellet V, Madore J, Ren F, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson AM: Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer. Br J Cancer 2006;94:436-445.

McNaught J, Reid RL, Provencher D, Lea R, Jeffrey J, Oza A, Swenerton K: Progesterone-only and non-hormonal contraception in the breast cancer survivor : Joint review and committee opinion of the Society of Obstetricians and Gynaecologists of Canada and the Society of Gynecologic Oncologists of Canada. J Obstet Gynaecol Can 2006;28:616-639.

Oros KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, Foulkes WD, Provencher D, Tonin PN: Application of brca1 and brca2 mutation carrier prediction models in breast and/or ovarian cancer families of french canadian descent. Clinical Genetics 2006;70:320-329.

Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson AM, Foulkes WD, Ghadirian P, Provencher D, Tonin PN: Haplotype analysis suggest common founders in carriers of the recurrent brca2 mutation, 3398delaaaag, in french canadian hereditary breast and/ovarian cancer families. BMC Med Genet 2006;7:23.

Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM: Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 2006;119:599-607.

Ouellet V, Le Page C, Guyot MC, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM: Set complex in serous epithelial ovarian cancer. Int J Cancer 2006;119:2119-2126.

Petignat P, Bouchardy C, Sauthier P: [cervical cancer screening: Current status and perspectives]. Rev Med Suisse 2006;2:1308-1309, 1311-1302.

Petignat P, Jolicoeur M, Alobaid A, Drouin P, Gauthier P, Provencher D, Donath D, Van Nguyen T: Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial cancer recurrence. Gynecol Oncol 2006;101:445-449.

Provencher D: Intraperitoneal chemotherapy for ovarian cancer : A complex strategy but what an exciting avenue ! Bull Cancer 2006;93:959-960.

Sauthier PG, Belanger R, Provencher DM, Gauthier P, Drouin P: Clinical value of image-guided fine needle aspiration of retroperitoneal masses and lymph nodes in gynecologic oncology. Gynecol Oncol 2006;103:75-80.

Stuart G, Avall-Lundqvist E, du Bois A, et al.: 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. Ann Oncol 2005;16 Suppl 8:viii36-viii38.

Presneau N, Shen Z, Provencher D, et al.: Identification of novel variant, 1484delG in the 3'UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors. Int J Oncol 2005;26:1621-1627.

Presneau N, Dewar K, Forgetta V, et al.: Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2. Mol Carcinog 2005;43:141-154.

Petignat P, Hankins C, Walmsley S, et al.: Self-sampling is associated with increased detection of human papillomavirus DNA in the genital tract of HIV-seropositive women. Clin Infect Dis 2005;41:527-534.

Ouellet V, Provencher DM, Maugard CM, et al.: Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 2005;24:4672-4687.

Millaire M, Alobaid A, Gariepy G, Gauthier P: Metastatic adenocarcinoma of the cervix: a case report. J Obstet Gynaecol Can 2005;27:1113-1116.

Le LH, Swenerton KD, Elit L, et al.: Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies. Int J Gynecol Cancer 2005;15:799-806.

Gagne JP, Gagne P, Hunter JM, et al.: Proteome profiling of human epithelial ovarian cancer cell line TOV-112D. Mol Cell Biochem 2005;275:25-55.

East N, Alobaid A, Goffin F, et al.: Granulosa cell tumour: a recurrence 40 years after initial diagnosis. J Obstet Gynaecol Can 2005;27:363-364.

du Bois A, Quinn M, Thigpen T, et al.: 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16 Suppl 8:viii7-viii12.

Arcand SL, Provencher D, Mes-Masson AM, Tonin PN: OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer. Int J Oncol 2005;27:1315-1320.

Alobaid A, Goffin F, Lussier C, Drouin P: Aggressive angiomyxoma of the vulva or perineum: report of three patients. J Obstet Gynaecol Can 2005;27:1023-1026.

Presneau N, Mes-Masson AM, Ge B, et al.: Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene 2003;22:1568-1579.

Trudeau M, Stuart G, Hirte H, et al.: A phase II trial of JM-216 in cervical cancer: an NCIC CTG study. Gynecol Oncol 2002;84:327-331.

Tran-Thanh D, Koushik A, Provencher D, et al.: Detection of human herpes virus type 6 DNA in precancerous lesions of the uterine cervix. J Med Virol 2002;68:606-610.

Pearcey R, Brundage M, Drouin P, et al.: Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 2002;20:966-972.

Narod SA, Dube MP, Klijn J, et al.: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94:1773-1779.

Manderson EN, Presneau N, Provencher D, et al.: Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer. Mol Carcinog 2002;34:78-90.

Manderson EN, Mes-Masson AM, Novak J, et al.: Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. Genome Res 2002;12:112-121.

Helewa M, Levesque P, Provencher D, et al.: Breast cancer, pregnancy, and breastfeeding. J Obstet Gynaecol Can 2002;24:164-180; quiz 181-164.

Tonin PN, Hudson TJ, Rodier F, et al.: Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene 2001;20:6617-6626.

Thompson D, Easton D: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410-419.

Narod SA, Sun P, Ghadirian P, et al.: Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001;357:1467-1470.

Manning AP, Abelovich D, Ghadirian P, et al.: Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families. Hum Hered 2001;52:116-120.

Wang J, Mes-Masson AM, Tonin PN, et al.: Trisomy of chromosome 10 in two cases of ovarian carcinoma. Cancer Genet Cytogenet 2000;118:65-68.

Provencher DM, Lounis H, Champoux L, et al.: Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 2000;36:357-361.

Narod SA, Brunet JS, Ghadirian P, et al.: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000;356:1876-1881.

Manderson EN, Mes-Masson AM, Provencher D, Tonin PN: Mutations in a 10-bp polyadenine repeat of transforming growth factor beta-receptor type II gene is an infrequent event in human epithelial ovarian cancer. Clin Genet 2000;57:151-153.

Dion F, Mes-Masson AM, Seymour RJ, et al.: Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. Oncogene 2000;19:1466-1472.

Tonin PM, Mes-Masson AM, Narod SA, et al.: Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin Genet 1999;55:318-324.

Manning AP, Mes-Masson AM, Seymour RJ, et al.: Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites. Mol Carcinog 1999;24:218-225.

Dubuc-Lissoir J, S L, Brunet JS, et al.: Laparoscopic Radical Hysterectomy versus Abdominal Radical Hysterectomy : A non-randomized study. Journal SOGC 1999;21:943-950.

D. E, DM) BCLCiP: Cancer Risks in BRCA2 Mutations Carriers. J Natl Cancer Inst 1999;91:1310-1316.

Breast Cancer Linkage Consortium T: Cancer Risks in BRCA2 Mutation Carriers. J Natl Cancer Inst 1999;91:1310-1316.

Tonin PN, Mes-Masson AM, Futreal PA, et al.: Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 1998;63:1341-1351.

Soulez G, Oliva VL, Therasse E, Provencher D: Embolization of a large-neck aneurysm of the internal iliac artery with interlocking detachable coils: case report. Can Assoc Radiol J 1998;49:39-41.

Narod SA, Risch H, Moslehi R, et al.: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-428.

Lounis H, Mes-Masson AM, Dion F, et al.: Mapping of chromosome 3p deletions in human epithelial ovarian tumors. Oncogene 1998;17:2359-2365.

Godard B, Foulkes WD, Provencher D, et al.: Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. Am J Obstet Gynecol 1998;179:403-410.

Provencher DM, Lounis H, Fink D, et al.: Discordance in p53 mutations when comparing ascites and solid tumors from patients with serous ovarian cancer. Tumour Biol 1997;18:167-174.

Coutlee F, Mayrand MH, Provencher D, Franco E: The future of HPV testing in clinical laboratories and applied virology research. Clin Diagn Virol 1997;8:123-141.

Coutlee F, Provencher D, Gauthier J: Is there a clinical utility for HPV detection tests for screening preinvasive and invasive diseases of the uterine cervix ? Germs & Ideas 1996;2:40-44.

Trottier AM, Provencher D, Mes-Masson AM, et al.: Absence of human papillomavirus sequences in ovarian pathologies. J Clin Microbiol 1995;33:1011-1013.

Pomel C, Provencher D, Dauplat J, et al.: Laparoscopic staging of early ovarian cancer. Gynecol Oncol 1995;58:301-306.

Coutlee F, Provencher D, Voyer H: Detection of human papillomavirus DNA in cervical lavage specimens by a nonisotopic consensus PCR assay. J Clin Microbiol 1995;33:1973-1978.

Vial Y, Sauthier P, Maillard-Brignon C, Bossart H: [Complications from chorionic villus sampling and amniocentesis]. J Gynecol Obstet Biol Reprod (Paris) 1994;23:476-480.

Spuhler SC, Sauthier PG, Chardonnens EG, De Grandi P: A new vaginal extractor for laparoscopic surgery. J Am Assoc Gynecol Laparosc 1994;1:401-404.

Spuhler S, Pasche N, Sauthier P, et al.: [Value of penis endoscopy in sexual partners of women with condylomatous or dysplastic lesions]. J Gynecol Obstet Biol Reprod (Paris) 1994;23:660-664.

Sauthier P, Hohlfeld P, Mosimann F, Bossart H: [Liver transplantation and pregnancy: 1994 perspectives]. Arch Gynecol Obstet 1994;255 Suppl 2:S259-271.

Lounis H, Provencher D, Godbout C, et al.: Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp Cell Res 1994;215:303-309.

Spuhler S, Sauthier P, Chardonnens E, De Grandi P: [C.C.L. vaginal extractor for celioscopic surgery]. Arch Gynecol Obstet 1993;253 Suppl:S80-82.

Spuhler S, Sauthier P: [Current indications for colposcopic examination]. J Gynecol Obstet Biol Reprod (Paris) 1993;22:722-728.

Spuhler S, Chardonnens E, Sauthier P, de Grandi P: [The C.C.L. culdotomy extractor for laparoscopic surgery]. J Gynecol Obstet Biol Reprod (Paris) 1993;22:111.

Sauthier P, Spuhler S, De Grandi P: [Problems associated with extraction of tumors in surgical celioscopy]. Arch Gynecol Obstet 1993;253 Suppl:S69-79.

Provencher DM, Finstad CL, Saigo PE, et al.: Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer. Gynecol Oncol 1993;50:78-83.

Chardonnens E, Spuhler S, Sauthier P, De Grandi P: [Patient preparation and technical infrastructure in celioscopy]. Arch Gynecol Obstet 1993;253 Suppl:S61-68.

Swenerton K, Jeffrey J, Stuart G, et al.: Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992;10:718-726.

Rubin SC, Finstad CL, Hoskins WJ, et al.: Analysis of antigen expression at multiple tumor sites in epithelial ovarian cancer. Am J Obstet Gynecol 1991;164:558-563.

Rubin SC, Finstad CL, Hoskins WJ, et al.: Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance. Am J Obstet Gynecol 1990;163:69-73.

Finstad CL, Saigo PE, Rubin SC, et al.: Immunohistochemical localization of P-glycoprotein in adult human ovary and female genital tract of patients with benign gynecological conditions. J Histochem Cytochem 1990;38:1677-1681.

Audet-Lapointe P, Body G, Vauclair R, et al.: Vaginal intraepithelial neoplasia. Gynecol Oncol 1990;36:232-239.

Abu-Hamad A, Provencher D, Ganjei P, Penalver M: Lymphangioma circumscriptum of the vulva: case report and review of the literature. Obstet Gynecol 1989;73:496-499.

Provencher D, Valme B, Averette HE, et al.: HIV status and positive Papanicolaou screening: identification of a high-risk population. Gynecol Oncol 1988;31:184-190.

Grimard L, Genest P, Girard A, et al.: Prognostic significance of endometrial extension in carcinoma of the cervix. Gynecol Oncol 1988;31:301-309.

Ayoub J, Audet-Lapointe P, Methot Y, et al.: Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status. Gynecol Oncol 1988;31:327-337.

Genest P, Drouin P, Girard A, Gerig L: Stage III carcinoma of the endometrium: a review of 41 cases. Gynecol Oncol 1987;26:77-86.

Genest P, Drouin P, Gerig L, et al.: Prognostic factors in early carcinoma of the endometrium. Am J Clin Oncol 1987;10:71-77.

Kane C, Drouin P: Obstructive uropathy associated with endometriosis. Am J Obstet Gynecol 1985;151:207-211.

Gauthier P, Gore I, Shingleton HM, et al.: Identification of histopathologic risk groups in stage IB squamous cell carcinoma of the cervix. Obstet Gynecol 1985;66:569-574.

Muram D, Drouin P: Ovarian remnant syndrome. Can Med Assoc J 1982;127:399-400.

Muram D, Curry RH, Drouin P: Cytologic follow-up of patients with invasive cervical carcinoma treated by radiotherapy. Am J Obstet Gynecol 1982;142:350-354.

Drouin P, Nasah BT, Nkounawa F: The value of the Partogramme in the management of labor. Obstet Gynecol 1979;53:741-745.